An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity
Frontiers in Pharmacology · 26.06.2024 · 15
DOI: 10.3389/fphar.2024.1406247 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 26.06.2024. Verfasst von Sicong Xie und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation Medicine, School of Acupuncture-Moxibustion and Tuina and School of Health Preservation and Rehabilitation, Nanjing Univ…. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 211 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Anthracycline drugs mainly include doxorubicin, epirubicin, pirarubicin, and aclamycin, which are widely used to treat a variety of malignant tumors, such as breast cancer, gastrointestinal tumors, lymphoma, etc. With the accumulation of anthracycline drugs in the body, they can induce serious heart damage, limiting their clinical application. The mechanism by which anthracycline drugs cause cardiotoxicity is not yet clear. This review provides an overview of the different types of cardiac damage induced by anthracycline-class drugs and delves into the molecular mechanisms behind these injuries. Cardiac damage primarily involves alterations in myocardial cell function and pathological cell death, encompassing mitochondrial dysfunction, topoisomerase inhibition, disruptions in iron ion metabolism, myofibril degradation, and oxidative stress. Mechanisms of uptake and transport in anthracycline-induced cardiotoxicity are emphasized, as well as the role and breakthroughs of iPSC in cardiotoxicity studies. Selected novel cardioprotective therapies and mechanisms are updated. Mechanisms and protective strategies associated with anthracycline cardiotoxicity in animal experiments are examined, and the definition of drug damage in humans and animal models is discussed. Understanding these molecular mechanisms is of paramount importance in mitigating anthracycline-induced cardiac toxicity and guiding the development of safer approaches in cancer treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rehabilitation Medicine, School of Acupuncture-Moxibustion and Tuina and School of Health Preservation and Rehabilitation, Nanjing University of Chinese Medicine, Nanjing, China.
- Department of General Surgery, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
- College of Electronic and Optical Engineering and College of Flexible Electronics, Future Technology, Nanjing University of Posts and Telecommunications, Nanjing, China.
- Key Laboratory of Intelligent Pharmacy and Individualized Therapy of Huzhou, Department of Pharmacy, Changxing People's Hospital, Huzhou, China.
Zitieren
APA
Xie, S., Sun, Y., Zhao, X., Xiao, Y., Zhou, F., Lin, L., Wang, W., Lin, B., Wang, Z., Fang, Z., Wang, L., & Zhang, Y. (2024). An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1406247
Vancouver
Xie S, Sun Y, Zhao X, Xiao Y, Zhou F, Lin L, et al. An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1406247
BibTeX
@article{Xie2024,
author = {Xie, Sicong and Sun, Yuwei and Zhao, Xuan and Xiao, Yiqun and Zhou, Fei and Lin, Liang and Wang, Wei and Lin, Bin and Wang, Zun and Fang, Zixuan and Wang, Lei and Zhang, Yang},
title = {An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1406247}
}
EUVIMED